Impact Of Rising Cancer Prevalence On The Market: A Significant Driver Propelling The Cancer Anorexia-Cachexia Syndrome (CACS) Market In 2025

We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.

What Is the Cancer Anorexia-Cachexia Syndrome (CACS) Market Size and Projected Growth Rate?
The market size for the cancer anorexia-cachexia syndrome (CACS) has seen a rapid growth in the past few years. It is projected to increase from $3.51 billion in 2024 to $3.89 billion in 2025, reflecting a compound annual growth rate (CAGR) of 11.0%. Factors contributing to this historic growth include a rising number of cancer cases, higher awareness among healthcare providers, enhanced emphasis on improving cancer patients' quality of life, growth in clinical trials, as well as collaborations and partnerships within the pharmaceutical sector.

The market size for cancer anorexia-cachexia (CACS) is predicted to undergo speedy expansion in the upcoming years, reaching $5.84 billion in 2029, with a 10.7% compound annual growth rate (CAGR). The increase during the prediction period can be associated with the rise of cancer survival rates, escalated investments in oncology supportive care, advancements in personalized medicine, the shift towards multimodal treatments, and the expansion of the healthcare infrastructure. Furthermore, the forecast period is expected to showcase major trends like progress in palliative care, the creation of targeted therapies, technological advancements in drug delivery systems, AI incorporation in drug creation, and further development in personalized medicine.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21125

What Are the Major Segments in the Cancer Anorexia-Cachexia Syndrome (CACS) Market?
The cancer anorexia-cachexia syndrome (CACS) market covered in this report is segmented -

1) By Indication: Weight Loss Prevention, Appetite Loss, Muscle Wasting, Inflammation, Other Indications
2) By Therapeutics: Progestogen, Corticosteroid, Combination Therapy, Other Therapeutics
3) By Mechanism Of Action: Appetite Stimulants, Anti-inflammatory Agents, Hormone Therapies, Cannabinoids, Other Mechanism Of Actions
4) By Route of Administration: Oral, Intravenous, Subcutaneous, Transdermal, Other Route of Administration
5) By Application: Hospitals, Clinics, Home Care

Subsegments:
1) By Weight Loss Prevention: Nutritional Supplements, Metabolic Modulators
2) By Appetite Loss: Appetite Stimulants, Ghrelin Receptor Agonists
3) By Muscle Wasting: Anabolic Agents, Selective Androgen Receptor Modulators (SARMs)
4) By Inflammation: Anti-Inflammatory Drugs, Cytokine Inhibitors
5) By Other Indications: Combination Therapies, Supportive Care Interventions

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21125&type=smp

What Are The Driving Cancer Anorexia-Cachexia Syndrome (CACS) Market Evolution?
The rising occurrence of cancer is anticipated to fuel the expansion of the cancer anorexia-cachexia syndrome market. As a term, cancer encompasses a variety of diseases characterized by unregulated growth and proliferation of abnormal cells in a person's body. Factors like an aging populace, changes in lifestyle, exposure to the environment, enhanced methods of detection, amplified awareness, genetic predispositions, and infections associated with specific cancers have led to a global rise in cancer rates. The cancer anorexia-cachexia syndrome (CACS) tackles this issue by targeting the severe malnutrition and weight loss frequently observed in cancer patients, aiming to improve their general life quality and treatment outcomes. As an example, a report released by the Macmillan Cancer Support in August 2024 revealed that over three million people in the UK were living with cancer. This figure is predicted to grow to 3.5 million by 2025, four million by 2030, and 5.3 million by 2040. Therefore, the escalating prevalence of cancer serves as a catalyst for the growth in the cancer anorexia-cachexia syndrome market. Transactional Impact of Rising Healthcare Spending On The Market

Which Firms Dominate The Cancer Anorexia-Cachexia Syndrome (CACS) Market Segments?
Major companies operating in the cancer anorexia-cachexia syndrome (CACS) market are Pfizer Inc., Merck & Co. Inc., Ono Pharmaceutical Co. Ltd., Mundipharma International Limited, Yuhan Corporation, Helsinn Healthcare SA, AVEO Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Larix Bioscience LLC, Aeterna Zentaris Inc., Artelo Biosciences Inc., Sapphire Therapeutics Inc., Endevica Bio, AAVogen Inc., Actimed Therapeutics Ltd., Aphios Corporation, Betula Pharmaceuticals AB, Cannabics Pharmaceuticals Inc., Creative Medical Technology Holdings Inc., Abreos Biosciences Inc.

What Are the Major Trends Shaping the Cancer Anorexia-Cachexia Syndrome (CACS) Market?
Key businesses in the cancer anorexia-cachexia syndrome market are concentrating their efforts on creating novel solutions, with monoclonal antibody therapies being among such initiatives. The goal is to improve treatment success, patient outcomes, and to fill gaps in clinical needs. These therapies involve the use of laboratory-engineered antibodies that specifically target antigens found on cancer cells, enabling the immune system to identify and attack them more efficiently. For example, Pfizer Inc., an American pharmaceutical and biotechnology firm, reported promising outcomes from a Phase II clinical trial of ponsegromab in September 2024. This monoclonal antibody targets the Growth/Differentiation Factor 15 (GDF-15). The promising trial results indicate a potential new treatment option for patients struggling with this devastating ailment, which currently has limited effective treatments. The positive results from the Phase II trial indicate significant strides towards addressing the key inflammatory processes that lead to muscle and weight loss in cancer patients. The proposed treatment strategy aims to not only improve physical functionality but also enhance the quality of life for patients with cancer. This development is seen as a critical milestone in cancer care.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/cancer-anorexia-cachexia-syndrome-cacs-global-market-report

Which Is The Largest Region In The Cancer Anorexia-Cachexia Syndrome (CACS) Market?
North America was the largest region in the cancer anorexia-cachexia (CACS) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer anorexia-cachexia syndrome (CACS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Cancer Anorexia-Cachexia Syndrome (CACS) Market?
2. What is the CAGR expected in the Cancer Anorexia-Cachexia Syndrome (CACS) Market?
3. What Are the Key Innovations Transforming the Cancer Anorexia-Cachexia Syndrome (CACS) Industry?
4. Which Region Is Leading the Cancer Anorexia-Cachexia Syndrome (CACS) Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.